SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001725160-22-000187
Filing Date
2022-10-31
Accepted
2022-10-31 17:24:22
Documents
15
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A zntl-20211231.htm   iXBRL 10-K/A 88547
2 EX-23.1 exhibit231.htm EX-23.1 3486
3 EX-31.1 exhibit311.htm EX-31.1 9654
4 EX-31.2 exhibit312.htm EX-31.2 9914
  Complete submission text file 0001725160-22-000187.txt   341223

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20211231.xsd EX-101.SCH 1902
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20211231_lab.xml EX-101.LAB 39611
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20211231_pre.xml EX-101.PRE 21005
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20211231_htm.xml XML 19818
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39263 | Film No.: 221347224
SIC: 2834 Pharmaceutical Preparations